RxDoctor Payments Data

Joshua Falk, DO

Internal Medicine · Rockville Centre, NYNPI 1841496114

Payments from drug & device makers

$1,929in general payments, 2019–2025

Across 78 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$653
  • AbbVie$652
  • Pfizer$179
  • Merck$112
  • Urovant Sciences Inc$100
  • E.r. Squibb & Sons, L.L.C.$86
  • plus $147 from 5 others

What the payments were for

  • Food & beverage$1,929100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,929 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$296,325
Medicare patients
570
Services billed
2,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$7,472
Cefpodoxime Proxetil54$1,802
Albuterol Sulfate HfaAlbuterol Sulfate19$471
Doxycycline Hyclate12$246
Famotidine40$222
Potassium Chloride26$188
Levothyroxine Sodium17$150
Metoprolol Succinate11$130
Prednisone56$130
Omeprazole18$111
Furosemide37$97
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$94
Hydralazine Hcl13$92
Atorvastatin Calcium11$82
Tamsulosin Hcl13$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$179$7,47213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rockville Centre

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →